What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?

Journal of Chemotherapy

Volumn 21, Issue 5, 2009, Pages 566-572

  Cheng, X ^a,b   Moroney, J W ^a   Levenback, C F ^a   Fu, S ^a   Jaishuen, A ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Bevacizumab; Chemotherapy; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GEMCITABINE; LEUPRORELIN; TAXANE DERIVATIVE; TOPOTECAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FOLLOW UP; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PRIMARY TUMOR; PROTEINURIA; RASH; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VOMITING; ADENOCARCINOMA; AGED; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DRUG COMBINATION; FEMALE; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; UTERINE TUBE TUMOR;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, SEROUS; DRUG THERAPY, COMBINATION; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 75549091041     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.5.566     Document Type: Article

References (20)

1. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothe-lial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998; 153: 1249-1256.
2. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 2002;161:1917-1924.
3. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165-5171.
4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
5. Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ. A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer. 2004;90:810-814.
6. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21(10 Suppl): 187s-193s.
7. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
8. Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol. 2007;107:173-176.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Helm W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
10. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locallly recurrent or metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
11. Ramalingam SS. Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26(1):60-65.
12. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Chn Oncol. 2008;26(1):76-82.
13. Cannistra SA, Matulonis U, Penson R, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186.
14. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGFJ)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102:140-144.
15. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer. 2006;107:83-89.
16. Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008; 18(3) :400-406.
17. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006;102:134-139.
18. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and falopian tube cancer: a trial of the Chiacago, PMH, and California phase II Consortia. Gynecol Oncol. 2008;110(1):49 55.
19. Aghajanian C. The role of bevacizumab in ovarian cancer - an evolving story. Gynecol Oncol. 2006;102:131-133.
20. Frumovitz M, Sood AK, Vascular endothelial growth factor (VEGF) pathway as a therapeutioc target in gynecologic ma lignancies. Gynecol Oncol. 2007;104:768-778.